The office building of international biopharmaceutical company AstraZeneca. Cfoto | Future Publishing | Getty Images AstraZeneca on Monday said it plans to invest $50 billion in bolstering its U.S. manufacturing and research capabilities by 2030, becoming the latest pharmaceutical firm to ramp up its stateside spending in the wake of U.S. trade tariffs. The Anglo-Swedish biotech company, which is headquartered …
Read More »AstraZeneca to invest $50 billion in the U.S. as pharma tariffs weigh
